ATHENEX, INC. (NASDAQ:ATNX) Files An 8-K Results of Operations and Financial Condition

ATHENEX, INC. (NASDAQ:ATNX) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

Story continues below

On August14, 2017, Athenex, Inc. issued a press release announcing its financial results for the second quarter ended June30, 2017. A copy of the press release is attached hereto as Exhibit99.1 and is incorporated herein in its entirety by reference.

The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 2.02. Financial Statements and Exhibits.



99.1 Press release titled “Athenex, Inc. Announces Second Quarter 2017 Results” issued by the Company on August14, 2017.

Athenex, Inc. Exhibit
EX-99.1 2 d295451dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Athenex,…
To view the full exhibit click here


Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company’s Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.

ATHENEX, INC. (NASDAQ:ATNX) Recent Trading Information

ATHENEX, INC. (NASDAQ:ATNX) closed its last trading session up +0.96 at 14.61 with 131,075 shares trading hands.

An ad to help with our costs